MedTrace Logo

AL-54478 Proof of Concept Study

NCT01318252 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2014-07-31

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)

Interventions

DRUG

AL-54478 0.005%

DRUG

Latanoprost 0.005%

DRUG

AL-54478 Vehicle

Inactive ingredients used as a placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Ravaughn Williams · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318252 on ClinicalTrials.gov